Clinical Trials

Inclusion Criteria

• Male, 45 years of age or older.
• Diagnosis of prostate adenocarcinoma.
• Clinical stage T1c or T2a.
• Gleason score of 7 (3+4 or 4+3) or less.
• Three or fewer biopsy cores with prostate cancer.
• No single biopsy core with greater than 50% of tumor involvement.
• One, two, or three tumor suspicious regions identified on multiparametric MRI
• Negative radiographic indication of extra-capsular extent.
• A documented Karnofsky performance status of at least 70.
• Estimated survival of 5 years or greater, as determined by treating physician.
• Tolerance for anesthesia/sedation.
• Ability to give informed consent.
• MR-guided biopsy confirmation of one or more radiographically visible prostate lesion(s) with Gleason score of 7 (3+4 or 4+3) or less.

Exclusion Criteria

• Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI.
• History of other primary non-skin malignancy within previous three years.